Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features
Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features
Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features That May Further Augment The Therapeutic Potential Of MSCs In Inflammatory Diseases
Eterna Therapeutics將在ASGCT第27屆年會上介紹β2微球蛋白基因敲除IMSC系列的開發情況，該系列具有增強的免疫抑制活性和隱身功能，可能會進一步增強間充質幹細胞在炎性疾病中的治療潛力
- The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells
- The presentation is on Saturday, May 11th, 2024
- 該演講報告了具有增強免疫抑制活性和隱身特徵的β2微球蛋白基因敲除（B2M-KO）iMSC系列的開發情況，該系列可以通過排除批次間的不一致性、促進體內持久性和增強細胞的效應器功能，進一步增強間充質幹細胞治療炎症性疾病的治療潛力
- 演講將於 2024 年 5 月 11 日星期六舉行
CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy, taking place in Baltimore, Maryland.
馬薩諸塞州劍橋，2024年5月7日（環球新聞專線）——使用先進細胞工程技術開發變革性新藥的生物製藥公司Eterna Therapeutics Inc.（納斯達克股票代碼：ERNA）（“Eterna” 或 “公司”）今天宣佈，雷文·欣克爾將出席在馬里蘭州巴爾的摩舉行的美國基因與細胞療法學會第27屆年會。
While mesenchymal stem cells (MSCs) have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses. This variability is often attributed to donor and source heterogeneity and limited expansion potential. Furthermore, MSCs can exhibit limited in vivo persistence due to clearance by host immune cells, which can also contribute to deficient therapeutic responses. Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) promise to directly address many of the fundamental challenges facing MSC translation.
儘管間充質幹細胞（MSC）在許多臨床前模型中一再顯示出巨大的治療潛力，但其臨床轉化卻因治療反應的變異而受到極大阻礙。這種變異性通常歸因於捐贈者和來源的異質性以及有限的擴張潛力。此外，由於宿主免疫細胞的清除，間充質幹細胞在體內的持久性可能有限，這也可能導致治療反應不足。誘導多能幹細胞 (iPSC) 衍生的間充質幹細胞 (IMSC) 有望直接解決 MSC 翻譯面臨的許多基本挑戰。
Here, we report the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells.
在這裏，我們報告了一種具有增強免疫抑制活性和隱身特徵的β2微球蛋白基因敲除（B2M-KO）iMSC系列的開發情況，該系列可以通過排除批次間的不一致性、促進體內持久性和增強細胞的效應功能，進一步增強間充質幹細胞治療炎症性疾病的治療潛力。
The abstract concludes that B2M-KO iMSCs are more likely to evade immune clearance and exert their immunomodulatory effects, as demonstrated by their enhanced sensitivity of IDO1 expression and their improved ability to inhibit PBMC proliferation. Our data suggest that B2M-KO iMSCs may be a promising therapeutic agent for T-cell mediated autoimmune and inflammatory indications.
摘要得出結論，B2M-KO IMSC更有可能逃避免疫清除併發揮其免疫調節作用，其增強的IDO1表達靈敏度以及抑制PBMC增殖的能力提高就證明了這一點。我們的數據表明，B2M-KO IMSC可能是治療T細胞介導的自身免疫和炎症適應症的有前途的治療藥物。
"We are thrilled to advance our iMSC research," says Sanjeev Luther, President and CEO. "iPSC-Derived iMSCs drive our Multiple Sclerosis pipeline candidate and are an important scientific focus for our team."
總裁兼首席執行官桑傑夫·路德說：“我們很高興能推進我們的iMSC研究。”“iPSC衍生的IMSC推動了我們的多發性硬化症候選藥物的發展，也是我們團隊重要的科學重點。”
Presentation Details
演示詳情
Title: iMSCs Derived from mRNA-Engineered B2M-KO iPSCs Exhibit Enhanced Immunosuppressive Activity and Stealthing Features
標題：源自 mRNA 設計的 B2M-KO iPSC 的 IMSC 具有增強的免疫抑制活性和隱身特性
Presenter: Raven Dance Hinkel, Research Associate II
主持人：Raven Dance Hinkel，二級研究助理
Date: Saturday, May 11, 2024
日期：2024 年 5 月 11 日星期六
Time: 10:30am - 10:45am
時間：上午 10:30-上午 10:45
Session Title: Novel Immune Effector Cell Manufacturing
會議標題：新型免疫效應細胞製造
Session Room: Ballroom 2
會議室：宴會廳 2
Location: Baltimore Convention Center in Baltimore, MD
地點：馬里蘭州巴爾的摩的巴爾的摩會議中心
譯文內容由第三人軟體翻譯。